芦可替尼联合阿扎胞苷治疗骨髓纤维化患者的2期研究
这项开放标签、非随机、前瞻性2期研究纳入46例骨髓纤维化患者,先连续接受芦可替尼治疗3个周期,自第4周期起加用阿扎胞苷25 mg/m2(第1-5天)并可增至75 mg/m2。中位随访28个月,33例(72%)达到IWG-MRT缓解,中位起效时间1.8个月;24周和研究中任意时间可触及脾长度缩小>50%者分别占可评估患者的62%和71%,24个月时57%的患者骨髓网状纤维化分级改善。
要点
- 46例骨髓纤维化患者中33例(72%)达到IWG-MRT缓解,中位起效时间1.8个月。
- 24周和任意时间脾长度缩小>50%者分别占可评估患者的62%和71%。
- 24个月时57%的患者骨髓网状纤维化分级改善,4例(9%)因药物相关毒性停药。
核心结论
- 芦可替尼联合阿扎胞苷安全,在骨髓纤维化患者中脾缓解率令人鼓舞并改善骨髓纤维化。
研究设计与样本
- 开放标签、非随机、前瞻性2期研究,纳入46例骨髓纤维化患者。
- 前3个周期连续每日两次接受芦可替尼,自第4周期起加用阿扎胞苷25 mg/m2(第1-5天),后续可增至75 mg/m2(第1-5天)。
- 中位随访28个月(范围4至50+个月)。
主要发现
- 33例(72%)达到IWG-MRT缓解,中位起效时间1.8个月(范围0.7-19.0个月)。
- 33例IWG-MRT缓解中有7例(四分之一)在加用阿扎胞苷后出现。
- 24周和研究中任意时间可触及脾长度缩小>50%者分别占可评估患者的62%和71%。
- 24周时脾长度缩小>50%的患者中,95%在48周时维持该缩小。
- 24个月时57%的患者骨髓网状纤维化分级改善。
关键数值与推荐
- 4例(9%)因药物相关毒性停药,均为血细胞减少所致。
- 新发3至4级贫血和血小板减少分别发生在35%和26%的患者中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib (RUX)-based combinations may provide benefit for patients with myelofibrosis (MF). In this open-label, nonrandomized, prospective phase 2 study, patients with MF initially received RUX twice per day continuously in 28-day cycles for the first 3 cycles. Azacitidine (AZA) 25 mg/m2 (days 1-5) was added starting with cycle 4 and could be subsequently increased to 75 mg/m2 (days 1-5). Forty-six patients were enrolled with a median follow-up of 28 months (range, 4-50+ months). An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) response was achieved in 33 patients (72%), with a median time to response of 1.8 months (range, 0.7-19.0 months). One-fourth (7 of 33) of the IWG-MRT responses occurred after the addition of AZA. A reduction of >50% in palpable spleen length at 24 weeks and at any time on the study was achieved in 62% and 71% of the evaluable patients, respectively. Among patients who achieved a >50% reduction in spleen length at 24 weeks, 95% had maintained it at 48 weeks. Notably, improvements in bone marrow reticulin fibrosis grade occurred in 57% of the patients at 24 months. Treatment discontinuations as a result of drug-related toxicities occurred in 4 patients (9%), all as a result of cytopenias. New onset grade 3 to 4 anemia and thrombocytopenia occurred in 35% and 26% of patients, respectively. RUX and AZA were safe, with encouraging spleen response rates and improvement in bone marrow fibrosis in patients with MF. This trial was registered at www.clinicaltrials.gov as #NCT01787487.
引用
- Masarova L, Verstovsek S, Hidalgo-Lopez JE, et al. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018. PMID: 30185431. doi:10.1182/blood-2018-04-846626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。